News Press Releases

2020/03/21 Reven News Press

Reven will soon kick off a social media campaign to get the word out about the exciting developments relative to RJX moving through the regulatory pathway. Please seek us out on Facebook, Instagram, Twitter, LinkedIn and like/comment on our posts … Read More

2019/01/22 Reven News Press

Kevin McGovern Joins Reven’s Board of Directors. Reven announces Kevin McGovern as the newest addition to its Board of Directors. Kevin McGovern Press Release

2019/01/17 Reven News Press

Reven Hires Dr. James Carlson. Dr. James Carlson hired as Reven’s Executive Vice President of Development Dr. James Carlson Press Release here: Reven Press Release – 011719  

2019/01/15 Reven News Press

On January 15, 2019 Reven completed their single-ascending-dose (SAD)/ multiple-ascending-dose (MAD) Phase 1 Clinical Trial in the United States. Reven is now in the planning stage of their Phase 2 Clinical Trial that will be conducted in the United States … Read More

2019/01/15 Reven News Press

MAD Cohort 3 completed dosing on January 15, 2019.

2019/01/04 Reven News Press

Reven Hires Susan Moore. Susan Moore hired as Reven’s Senior Director of Regulatory and Clinical Affairs.

2019/01/08 Reven News Press

MAD Cohort 3 begins seven-day dosing period.

2018/12/19 Reven News Press

Reven Hires Natalie Pizzimenti. Natalie Pizzimenti hired as Reven’s Clinical Research Scientist.

2018/12/18 Reven News Press

MAD Cohort 2 completed dosing on December 18, 2018.

2018/12/11 Reven News Press

MAD Cohort 2 begins seven-day dosing period.

2018/12/05 Reven News Press

SAD Cohort 6C doses subjects; SAD Cohort 6 is completed.

2018/12/03 Reven News Press

Reven Hires Crysta Huszai. Crysta Huszai hired as Reven’s Quality Specialist.

2018/11/30 Reven News Press

SAD Cohort 6b dosing completed.

2018/11/27 Reven News Press

SAD Cohort 6 Underway. SAD Cohort 6A doses subjects.

2018/11/19 Reven News Press

MAD Cohort 1 Completed.